Personal Capital Advisors’s Immune Design Corp. IMDZ Stock Holding History

Personal Capital Advisors’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-37,500	Closed	-$49K	–	347
2018 Q4	$49K	Buy	37,500 +13,500	+56%	+$23.5K	﹤0.01%	305
2018 Q3	$83K	Hold	24,000	–	–	﹤0.01%	291
2018 Q2	$109K	Hold	24,000	–	–	﹤0.01%	273
2018 Q1	$79K	Hold	24,000	–	–	﹤0.01%	259
2017 Q4	$94K	Sell	24,000 -9,056	-27%	-$49.3K	﹤0.01%	251
2017 Q3	$342K	Sell	33,056 -3,444	-9%	-$33.9K	0.01%	190
2017 Q2	$356K	Buy	+36,500	New	+$256K	0.01%	189

Other funds holding IMDZ

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

SAM

Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Personal Capital Advisors's IMDZ Position: Q1 2019 in Review

Personal Capital Advisors sold out of Immune Design Corp. (IMDZ) in Q1 2019, closing a stake of 37,500 shares — an estimated $49K sold.

Personal Capital Advisors first reported a position in IMDZ in Q2 2017 and held it in 7 quarters. The position peaked at $356K in Q2 2017. 68 funds tracked by Wall St. Rank hold IMDZ as of Q1 2019.

Personal Capital Advisors reported no remaining Immune Design Corp. position as of Q1 2019 after selling out during the quarter.
Personal Capital Advisors sold 37,500 Immune Design Corp. shares in Q1 2019, an estimated $49K.
Personal Capital Advisors first reported a position in Immune Design Corp. in Q2 2017 and held it in 7 quarters.
Personal Capital Advisors's Immune Design Corp. position peaked at $356K in Q2 2017.
68 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2019.

Based on Personal Capital Advisors's 13F filing for Q1 2019, filed 13 May 2019.